Aubagio
Teriflunomide tablets for relapsing remitting multiple sclerosis. It reduces the overactive immune response that damages nerve fibres in the brain and spinal cord.
- Categories
- Neurology · Autoimmune Support
- Active ingredient
- Teriflunomide
- Route
- Oral use
- Form
- Tablet; Film-coated tablet
- Strengths
- 14mg
This listing uses Aubagio as a reference name. A generic equivalent is supplied; its exact brand and manufacturer are confirmed before supply.
Prescription and consultation requirements for Aubagio vary by destination and are determined by the fulfilment partner.
Aubagio details
- Conditions
- Relapsing Remitting Multiple Sclerosis · Clinically Isolated Syndrome · Relapsing-remitting Multiple Sclerosis · Active Secondary Progressive Multiple Sclerosis
- Therapeutic class
- Selective immunosuppressants
- Pharmacological class
- Pyrimidine synthesis inhibitor; Dihydroorotate dehydrogenase inhibitor
- Dosage forms
- Tablet; Film-coated tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Originator
- Sanofi
- Storage instructions
- Store below 25°C. Keep in the original package to protect from moisture.
Contraindications
severe hepatic impairment; pregnancy; females of reproductive potential not using effective contraception; hypersensitivity to teriflunomide, leflunomide or any excipient; severe immunodeficiency states; significantly impaired bone marrow function; serious active infection; severe hypoproteinaemia; co-administration with leflunomide
Precautions and warnings
hepatotoxicity requiring monitoring of transaminase and bilirubin levels; bone marrow effects and immunosuppression potential; risk of serious infections; hypersensitivity reactions including anaphylaxis and serious skin reactions; peripheral neuropathy; increased blood pressure; respiratory effects including interstitial lung disease; tuberculosis screening prior to treatment; full blood count monitoring; accelerated elimination procedure with colestyramine or activated charcoal available
Minor side effects
headache; diarrhoea; nausea; alanine aminotransferase increased; alopecia; paraesthesia; fatigue; influenza
Moderate side effects
hepatitis; severe liver injury; pancreatitis; interstitial lung disease; peripheral neuropathy; severe infections; neutropenia; lymphopenia; leukopenia; thrombocytopenia; stevens-Johnson syndrome; toxic epidermal necrolysis; drug reaction with eosinophilia and systemic symptoms; hypertension; angioedema; anaphylaxis
Serious side effects
acute liver failure, requires immediate medical attention; stevens-Johnson syndrome, requires immediate medical attention; toxic epidermal necrolysis, requires immediate medical attention; anaphylaxis, requires immediate medical attention; serious infection, requires immediate medical attention; pancreatitis, requires immediate medical attention; interstitial lung disease, requires immediate medical attention
Patient summary
Teriflunomide tablets for relapsing remitting multiple sclerosis. It reduces the overactive immune response that damages nerve fibres in the brain and spinal cord.
Mechanism of action
Aubagio contains teriflunomide, an immunomodulatory medicine that selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase. This enzyme is needed by rapidly dividing cells, including activated lymphocytes that drive the immune attack on myelin in multiple sclerosis. By reducing the proliferation of these activated immune cells, Aubagio helps decrease inflammation and damage to the protective covering of nerves, thereby reducing the number of relapses and slowing the progression of disability.
Drug interactions
leflunomide; immunosuppressive agents; immunomodulating therapies; hepatotoxic drugs; warfarin; oral contraceptives; colestyramine; activated charcoal; repaglinide; pioglitazone; rosuvastatin; methotrexate; live vaccines; rifampicin; St John's wort
Age restrictions
Approved for adults aged 18 years and over and paediatric patients aged 10 years and older (EU). Safety and efficacy in children under 10 years not established.
Pregnancy and breastfeeding
Pregnancy: Aubagio is contraindicated in pregnancy. Teriflunomide caused teratogenicity and embryolethality in animal studies at exposures lower than human therapeutic levels. Pregnancy must be excluded before starting treatment. Females of reproductive potential must use effective contraception during treatment and after discontinuation until plasma teriflunomide levels are below a specified threshold. If pregnancy occurs, an accelerated elimination procedure with colestyramine or activated charcoal should be initiated to rapidly lower plasma levels. Breastfeeding: Contraindicated during treatment with teriflunomide.
What you will receive
Aubagio is used here as a reference originator brand name to identify the medicine. We are not affiliated with the brand owner, and this listing does not offer the originator product.
- The supplied product is a generic equivalent containing Teriflunomide, not the originator brand shown as the reference.
- The exact generic brand, manufacturer and dispatch location are confirmed based on the product, destination and available manufacturer or partner warehouse.
- Check the final product details at checkout before confirming an order.